The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | GBT021601, a next generation HbS polymerization inhibitor for the treatment of SCD
Clark Brown, MD, PhD, Aflac Cancer & Blood Disorders Center, Atlanta, GA, outlines the mechanism of action of GBT021601, a next-generation sickle hemoglobin (HbS) polymerization inhibitor developed for the treatment of sickle cell disease (SCD), highlighting the results of Phase I studies evaluating this agent. The study reported that the drug was well-tolerated and led to significantly increased hemoglobin levels. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Consultancy: Global Blood Therapeutics, Imara, Novartis, Novo Nordisk; Research support: Global Blood Therapeutics, Forma Therapeutics, Imara, Novartis, Pfizer
